Editorial 2: Efficacy and Safety Outcomes in Clinical Trials of Proprotein Convertase Subtilisin-Kexin (PCSK) Type 9 Inhibitors in Coronary Artery Disease

By  

World Heart Journal, Vol. , Iss. , 2017-01 ,pp. : 15-18

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 14, Iss. 2, 2017-01 ,pp. : 94-100

Bentham Science Publishers

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 11, Iss. 4, 2013-12 ,pp. : 281-288

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review

By  

Current Cardiology Reviews, Vol. 13, Iss. 4, 2017-10 ,pp. : 274-282

Bentham Science Publishers

Access to resources Recommend Favorite

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 5, 2016-05 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite